SOPHiA GENETICS (NASDAQ:SOPH) Price Target Raised to $9.00

SOPHiA GENETICS (NASDAQ:SOPH) had its price target boosted by BTIG Research from $8.00 to $9.00 in a research note published on Wednesday, Marketbeat reports. They currently have a buy rating on the stock.

Several other research firms also recently commented on SOPH. Zacks Research raised SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. HC Wainwright increased their price target on SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $10.00.

SOPHiA GENETICS Price Performance

Shares of SOPH stock opened at $7.71 on Wednesday. The company has a market capitalization of $646.79 million, a P/E ratio of -6.70 and a beta of 0.96. The company’s 50-day simple moving average is $5.63 and its two-hundred day simple moving average is $5.15. SOPHiA GENETICS has a one year low of $2.96 and a one year high of $7.86. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 1.90.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The company had revenue of $23.31 million for the quarter, compared to the consensus estimate of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. As a group, equities analysts anticipate that SOPHiA GENETICS will post -0.77 EPS for the current year.

Insider Activity

In related news, CEO Ross Muken sold 9,838 shares of the business’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $5.22, for a total value of $51,354.36. Following the completion of the transaction, the chief executive officer owned 670,651 shares of the company’s stock, valued at $3,500,798.22. The trade was a 1.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Zhenyu Xu sold 17,000 shares of the company’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $7.29, for a total value of $123,930.00. Following the sale, the insider owned 590,887 shares of the company’s stock, valued at approximately $4,307,566.23. This represents a 2.80% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 276,092 shares of company stock worth $1,637,350. Corporate insiders own 4.88% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of SOPHiA GENETICS by 246.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after purchasing an additional 5,432,871 shares during the last quarter. Akre Capital Management LLC grew its stake in SOPHiA GENETICS by 66.2% in the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after purchasing an additional 1,481,636 shares during the last quarter. Hodges Capital Management Inc. purchased a new position in SOPHiA GENETICS in the first quarter valued at about $2,157,000. Royce & Associates LP bought a new position in SOPHiA GENETICS in the fourth quarter worth about $2,009,000. Finally, Sei Investments Co. bought a new position in SOPHiA GENETICS in the first quarter worth about $1,772,000. 31.59% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: BTIG Research raised its price target for SOPH from $8 to $9 while maintaining a Buy rating. The move adds to recent analyst support and reinforces the stock’s upward momentum. BTIG Research raises SOPHiA GENETICS price target
• Positive Sentiment: SOPHiA GENETICS reached a new 12-month high following the analyst upgrade, indicating strong investor demand and a favorable near-term trading reaction. SOPHiA GENETICS reaches a new 12-month high
• Positive Sentiment: HC Wainwright continues to rate SOPH Buy with a $14 price target, well above recent trading levels. Its longer-term forecast still calls for a return to profitability, including positive EPS estimates for 2029 and 2030.
• Neutral Sentiment: Chief Technology Officer Abhimanyu Verma sold 5,000 shares for approximately $34,750 under a pre-arranged Rule 10b5-1 plan. Because the sale was scheduled in advance and reduced his ownership by only 2.6%, it carries limited signaling value.
• Negative Sentiment: HC Wainwright lowered EPS estimates across several periods: Q3 2026 to $(0.13), FY2026 to $(0.77) from $(0.58), FY2027 to $(0.31) from $(0.20), and FY2028 to $(0.02) from positive $0.04. Estimates for Q1–Q4 2027 were also reduced, suggesting profitability may arrive later than previously expected.
• Negative Sentiment: The company’s latest quarterly loss of $(0.26) per share exceeded the expected $(0.21) loss, highlighting ongoing profitability pressure despite revenue exceeding expectations. SOPH remains deeply unprofitable, which could limit further gains if growth or the path to breakeven weakens.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.